NCT06126796Completed
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
A Randomized Cross-Over Study to Evaluate Patient Preference and Satisfaction With Urine-based Molecular Testing Versus Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 107 (actual)
- First submitted
- 7 Nov 2023
- Start date
- 16 Nov 2023
- Primary completion date
- 8 Sept 2025
- Lead sponsor
- Mayo Clinic
- Diseases
- Bladder cancer
- NCT number
- NCT06126796
What you commit to
- Study type: Observational
- Participants enrolled: 107
- From 16 Nov 2023 to the primary completion date, 8 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma)
- Patients with a history of upper tract and/or urethral cancer
Other
- Patients with predominant (\>50%) variant histology
- Women who are pregnant
Who the study is looking for
- Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence.
- Able to provide urine for testing and comply with study protocol.
- Have an email address and be willing to complete surveys online.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Arizona Coordinator of this site? Confirm its status | Scottsdale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.